A share price of Oramed Pharmaceuticals, Inc [ORMP] is currently trading at $3.68, up 6.98%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ORMP shares have gain 15.09% over the last week, with a monthly amount glided 28.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Oramed Pharmaceuticals, Inc [NASDAQ: ORMP] stock has seen the most recent analyst activity on January 12, 2023, when Canaccord Genuity downgraded its rating to a Hold and also revised its price target to $3 from $30. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on February 18, 2022, and set its price target to $20. On April 20, 2021, Canaccord Genuity initiated with a Buy rating and assigned a price target of $27 on the stock. National Securities started tracking the stock assigning a Buy rating. Alliance Global Partners initiated its recommendation with a Buy and recommended $11 as its price target on December 03, 2020. Aegis Capital started tracking with a Buy rating for this stock on March 11, 2020, and assigned it a price target of $5.50. In a note dated September 11, 2019, Ladenburg Thalmann initiated an Buy rating and provided a target price of $7 on this stock.
Oramed Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $1.70 and $3.46. Oramed Pharmaceuticals, Inc [NASDAQ: ORMP] shares were valued at $3.68 at the most recent close of the market.
Analyzing the ORMP fundamentals
Gross Profit Margin for this corporation currently stands at -0.04% with Operating Profit Margin at -6.51%, Pretax Profit Margin comes in at 27.87%, and Net Profit Margin reading is 21.93%. To continue investigating profitability, this company’s Return on Assets is posted at 0.2, Equity is 0.27 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Oramed Pharmaceuticals, Inc [NASDAQ:ORMP] is 22.24. As well, the Quick Ratio is 22.24, while the Cash Ratio is 8.53. Considering the valuation of this stock, the price to sales ratio is 73.23, the price to book ratio is 0.74 and price to earnings (TTM) ratio is 3.67.
